- Home
- VIVS vs KTTA Comparison
VIVS vs KTTA Comparison
Compare VIVS & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- KTTA
- Stock Information
- Founded
- VIVS 2007
- KTTA 2020
- Country
- VIVS United States
- KTTA United States
- Employees
- VIVS N/A
- KTTA N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- KTTA Health Care
- Exchange
- VIVS Nasdaq
- KTTA Nasdaq
- Market Cap
- VIVS 5.0M
- KTTA 5.1M
- IPO Year
- VIVS N/A
- KTTA 2021
- Fundamental
- Price
- VIVS $2.21
- KTTA $0.75
- Analyst Decision
- VIVS
- KTTA
- Analyst Count
- VIVS 0
- KTTA 0
- Target Price
- VIVS N/A
- KTTA N/A
- AVG Volume (30 Days)
- VIVS 70.9K
- KTTA 111.3K
- Earning Date
- VIVS 08-05-2025
- KTTA 08-12-2025
- Dividend Yield
- VIVS N/A
- KTTA N/A
- EPS Growth
- VIVS N/A
- KTTA N/A
- EPS
- VIVS N/A
- KTTA N/A
- Revenue
- VIVS $144,000.00
- KTTA N/A
- Revenue This Year
- VIVS $42.38
- KTTA N/A
- Revenue Next Year
- VIVS $15.42
- KTTA N/A
- P/E Ratio
- VIVS N/A
- KTTA N/A
- Revenue Growth
- VIVS 32.11
- KTTA N/A
- 52 Week Low
- VIVS $1.41
- KTTA $0.65
- 52 Week High
- VIVS $21.96
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- VIVS N/A
- KTTA 49.09
- Support Level
- VIVS N/A
- KTTA $0.68
- Resistance Level
- VIVS N/A
- KTTA $0.75
- Average True Range (ATR)
- VIVS 0.00
- KTTA 0.03
- MACD
- VIVS 0.00
- KTTA 0.01
- Stochastic Oscillator
- VIVS 0.00
- KTTA 95.20
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).